Christophe Vandenbriele, MD, discusses data on combining Impella® with MitraClip to optimize outcomes in cardiogenic shock with acute severe mitral regurgitation secondary to AMI.
Dave Weber, PhD, reviews how SmartAssist technology determines and tracks trends in cardiac output (CO) and cardiac power output (CPO) and how these metrics can be used to guide a successful Impella® heart pump weaning procedure.
Marvin Slepian, MD, compares the hemocompatibility of Impella 5.5 to Centrimag discussing hemolysis, platelet activation, microparticle generation, and vWF alteration.
William O'Neill, MD, shares insights from the National Cardiogenic Shock Initiative (NCSI) Study that are driving improved outcomes in patients with AMI cardiogenic shock.
NPS-1674
This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.